- Home
- PCRX vs CRVS Comparison
PCRX vs CRVS Comparison
Compare PCRX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- CRVS
- Stock Information
- Founded
- PCRX 2006
- CRVS 2014
- Country
- PCRX United States
- CRVS United States
- Employees
- PCRX N/A
- CRVS N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- PCRX Health Care
- CRVS Health Care
- Exchange
- PCRX Nasdaq
- CRVS Nasdaq
- Market Cap
- PCRX 1.2B
- CRVS 335.1M
- IPO Year
- PCRX 2011
- CRVS 2016
- Fundamental
- Price
- PCRX $26.59
- CRVS $5.32
- Analyst Decision
- PCRX Buy
- CRVS Strong Buy
- Analyst Count
- PCRX 10
- CRVS 5
- Target Price
- PCRX $29.30
- CRVS $12.38
- AVG Volume (30 Days)
- PCRX 892.8K
- CRVS 516.8K
- Earning Date
- PCRX 02-27-2025
- CRVS 03-18-2025
- Dividend Yield
- PCRX N/A
- CRVS N/A
- EPS Growth
- PCRX N/A
- CRVS N/A
- EPS
- PCRX N/A
- CRVS N/A
- Revenue
- PCRX $694,957,000.00
- CRVS N/A
- Revenue This Year
- PCRX $5.14
- CRVS N/A
- Revenue Next Year
- PCRX $2.44
- CRVS N/A
- P/E Ratio
- PCRX N/A
- CRVS N/A
- Revenue Growth
- PCRX 4.40
- CRVS N/A
- 52 Week Low
- PCRX $11.16
- CRVS $1.30
- 52 Week High
- PCRX $31.67
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- PCRX 77.75
- CRVS 42.39
- Support Level
- PCRX $25.06
- CRVS $5.02
- Resistance Level
- PCRX $27.10
- CRVS $5.58
- Average True Range (ATR)
- PCRX 1.45
- CRVS 0.33
- MACD
- PCRX 0.28
- CRVS 0.08
- Stochastic Oscillator
- PCRX 86.23
- CRVS 52.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).